Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

25.13 +0.19 (+0.76%)
Official Closing Price Updated: 7:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
99 100 Next >
(PFE) - Analyzing Pfizer's Short Interest
Via Benzinga
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields
Via Benzinga
How To Earn $500 A Month From Pfizer Stock Ahead Of Q2 Earnings
Pfizer Inc (PFE) expected to release Q2 financial results on Tuesday before opening bell. Analysts predict earnings at 46 cents/share, down from 67 cents last year. Stock gained 3.4% to close at $30.77... 
Via Benzinga
Prediction: This Will Be Pfizer's Next Big Move
One market in particular is too lucrative for it to miss out on any longer. 
Via The Motley Fool
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say following its July meeting. 
Via Benzinga
Topics Economy
Exposures Interest Rates
3 Ultra-High-Yield Dividend Stocks to Buy Now and Hold Forever
Any of these three stocks could be the backbone of a solid dividend portfolio. 
Via The Motley Fool
Pfizer's Options: A Look at What the Big Money is Thinking
Via Benzinga
2 Incredibly Cheap Healthcare Stocks to Buy Now
Sometimes a beaten-down stock can present a valuable opportunity. 
Via The Motley Fool
2 High-Yield Dividend Stocks That Could Shine in 2025
With interest rates expected to decline, high-yield dividend stocks offer attractive income potential and possible capital appreciation. 
Via The Motley Fool
2 Unstoppable Growth Stocks to Buy Right Now for Less Than $200
These stocks are trading on sale, but a closer look from investors is warranted. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
3 Surprisingly Underrated Stocks to Buy Right Now
These stocks arguably deserve more respect from investors. 
Via The Motley Fool
Freeport-McMoRan, Pfizer, Danaher And An Industrial Stock: CNBC's 'Final Trades'
Freeport-McMoRan is Bryn Talkington's "final trade." On July 23, Freeport-McMoRan said second-quarter revenue came in at $6.62 billion. 
Via Benzinga
Get Your Money Out of These 3 Dividend Stocks by 2025
Discover the three dividend stocks you should sell by 2025 for better returns. Get insights into why these 3 stocks could disappoint you. 
Via InvestorPlace
What's Going On With Pfizer Stock Thursday?
Pfizer is anticipated to report quarterly financial earnings on Tuesday before the market opens. In addition, the European Commission approved Pfizer's DURVEQTIX. 
Via Benzinga
European Commission Approves Pfizer’s DURVEQTIX® (fidanacogene elaparvovec), a One-Time Gene Therapy for Adults with Hemophilia B
From Pfizer Inc.
Via Business Wire
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:AXSM) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
7 Dividend Stocks to Hold On Tight to for the Next Decade
Discover the top long-term dividend stocks across pharmaceuticals, asset management, REITs, telecommunications, and tobacco. 
Via InvestorPlace
3 Stocks That Can Help You to Get Richer in 2024 and Beyond
Good bargains still abound in the market, and two of the stocks below offer fat dividends as well. 
Via The Motley Fool
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
From FN Media Group LLC
Via GlobeNewswire
Beware, Wegovy -- Pfizer Is Working on a Competitor
Pfizer wants to maintain its recent run of key approvals. 
Via The Motley Fool
Why Is Sangamo Therapeutics (SGMO) Stock Up 40% Today?
Little-known firm Sangamo Therapeutics is surging today, with SGMO stock up more than 40% on promising late-stage trial results. 
Via InvestorPlace
Sangamo Stock Spikes As Pfizer Partnership Meets Goal In Late-Stage Study
Pfizer's Phase 3 AFFINE study of giroctocogene fitelparvovec gene therapy for hemophilia A meets key endpoints, showing a significant reduction in annualized bleeding rate. 
Via Benzinga
This Promising Weight Loss Drug Candidate Could Be a Huge Growth Catalyst for Pfizer
With danuglipron, Pfizer could become a major player in the massive GLP-1 agonist market. 
Via The Motley Fool
Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On
Wegovy, a GLP-1 receptor agonist, had previously been approved for use in obesity treatment and weight management. 
Via Benzinga
Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate
From Pfizer Inc.
Via Business Wire
Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants
Merck shares topline results from its Phase 2b/3 trial of clesrovimab, showing efficacy in reducing RSV-related infections in infants. Clesrovimab met safety and efficacy endpoints. 
Via Benzinga
Pfizer And GSK's ViiV Healthcare's Two-Drug HIV Treatment Matches Gilead's Three-Drug Combo In Major Trial
ViiV Healthcare's Dovato matches Gilead's Biktarvy in effectiveness for HIV treatment. The study reveals Dovato's benefit of less weight gain compared to Biktarvy, highlighting its efficacy and patient... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier
Pharmaceutical giants like Roche, Eli Lilly, Novo Nordisk, and Pfizer are racing to develop oral weight loss medications. These drugs promise to complement existing injectables, offering new hope in... 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.